# A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

> clinical trial · VERIFIED · 2026-07-10

Status: RECRUITING · Sponsor: Merck Sharp & Dohme LLC · Condition: Triple Negative Breast Neoplasms

- Company: Merck Sharp & Dohme LLC
- Sector: Triple Negative Breast Neoplasms
- Primary source: https://clinicaltrials.gov/study/NCT06841354

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.